IR-MED Receives $500,000 Grant from the Israel Innovation Authority to Develop its Platform Technology for the Early Detection of Diabetic Foot Ulcers
IR-MED Inc. (OTCQB:IRME) has received a $500,000 grant from the Israel Innovation Authority to develop DiaSafe™, a device for early detection of diabetic foot ulcers. This marks the company's second IIA grant after peer review. DiaSafe™ uses AI-driven spectrographic analysis to provide non-invasive, real-time optical readings of biomarkers. The 13-month development is on schedule, with computer simulations completed and hardware construction underway.
Diabetic foot ulcers affect up to 183 million people globally, with 37 million potentially requiring amputation. Early detection can significantly improve patient outcomes and reduce healthcare costs in a $10 billion global treatment market. IR-MED's platform technology also powers PressureSafe™, a device for early pressure injury detection, expected to launch in the U.S. in H2 2024.
- Received $500,000 grant from Israel Innovation Authority
- Development of DiaSafe™ for early detection of diabetic foot ulcers on schedule
- Addressing a $10 billion global treatment market
- PressureSafe™ expected to launch in U.S. in second half of 2024
- None.
- DiaSafe™, IR-MED’s second product, is being developed to provide safe, real-time optical readings of biomarkers to detect the early presence of diabetic foot ulcers with high accuracy
- The most common cause of amputation, diabetic foot ulcers can be prevented with early detection, improving patient care and healthcare economics in a
$10 billion global treatment market - This marks the second grant that IR-Med has received from the Israel Innovation Authority after peer review of IR-MED's technology platform
Rosh Pina, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis technology platform to address significant healthcare needs, announced it has received a grant from the Israel Innovation Authority (IIA) in the amount of approximately
By sensing the invisible, DiaSafe™, IR-MED’s newest handheld device, is being designed to non-invasively analyze the biomarkers of blood and tissue, at the point of care, to help healthcare providers prevent diabetic foot ulcers from developing in their diabetic patients.
The Company believes an effective early detection device can reduce healthcare costs, save limbs, and save lives. Diabetic foot ulcers are more cost effective to manage in their initial stages. Detecting and treating diabetic foot ulcers early can significantly improve quality of life by reducing pain and increasing mobility. Early intervention can reduce death rate associated with diabetic foot complications.
Diabetic foot ulcers are a major cause of preventable death for people with diabetes, according to an article published in Diabetes Care, the journal of the American Diabetes Association. An estimated 537 million people globally have diabetes, and
IR-MED’s DiaSafe™ is based on the same platform technology as the Company’s lead device, PressureSafe™, a decision support device for the early detection of pressure injuries, which is expected to launch in the U.S. in the second half of 2024.
Ronnie Klein, IR-MED’s Chief Technology Officer and Interim Chief Executive Officer, commented, “We are honored to be selected by the IIA for a second grant. This
About IR-MED
IR-MED Inc. is developing a noninvasive spectrographic analysis technology platform, allowing healthcare professions to detect, measure and monitor, in real time, different molecules in the blood, in human tissue, and in body fluids without invasive procedures. PressureSafe, the first product under useability studies, is a handheld optical monitoring device that is being developed to support early detection of pressure injuries (PI) to the skin and underlying tissue, regardless of skin tone as it calibrates personally to each patient’s skin.
IR-MED’s technology is being developed to allow readings of biomarkers in a non-invasive method, that may provide caregiver the optimal decision support-system in cases where uncertainties disturb physicians in their decision processes.
IR-MED holds patents protecting its technology and innovations in the noninvasive tissue analysis, and in the modeling and analysis of subcutaneous tissue.
PressureSafe is currently undergoing usability studies at multiple medical centers.
Safe Harbor Statement / Forward-Looking Statements
Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For example, IR-Med is using forward-looking statements when it discusses the development of the DiaSafe™ device and its potential advantages, that the PressureSafe™ device is expected to be launched in the U.S. in the second half of 2024, and that the
Contact:
Sharon Levkoviz, Chief Financial Officer
Tel: +972 (0) 4 6555054
Attachment
FAQ
What is the purpose of the $500,000 grant IR-MED (IRME) received from the Israel Innovation Authority?
When is IR-MED (IRME) expected to launch PressureSafe™ in the United States?
How large is the global treatment market for diabetic foot ulcers that IR-MED (IRME) is targeting?